title: High-dose chemotherapy and immunotherapy in adult Burkitt lymphoma: comparison of results in human immunodeficiency virus-infected and noninfected patients.
abstract: BACKGROUND
  It has been recognized that cure is possible for human immunodeficiency virus (HIV)-infected patients with Burkitt lymphoma/leukemia (BL) if appropriate chemotherapy is used. The introduction of rituximab in BL therapeutic schemes has been scarcely explored. The outcome and toxicity of HIV-positive patients with BL treated in a rituximab and intensive chemotherapy-based trial was evaluated.
  
  
  METHODS
  Thirty-six consecutive patients, 15 to 55 years of age, diagnosed with advanced stage BL were recruited from July 2003 to August 2006, stratified according to HIV infection status and treated with 6 cycles of intensive chemotherapy including 8 doses of rituximab.
  
  
  RESULTS
  Nineteen of the patients (53%) were HIV-infected. Their clinical characteristics were comparable to those of the HIV-negative patients. Complete remission (CR) rates were 88% and 84%, respectively, for HIV-negative and -positive patients. Twenty-seven patients (82% and 68%, respectively, for HIV-negative and -positive patients) completed the 6 protocol scheduled cycles. HIV-infected patients presented higher incidences of grade 3-4 mucositis (27% vs 7% of cycles, P = .0005) and severe infectious episodes (26% vs 8%, P = .0025). However, there were no statistically significant differences in 2-year overall survival (82%, 95% confidence interval [CI], 65%-99% and 73%, 95% CI, 54%-92%, respectively) or 2-year disease-free survival (93%, 95% CI, 82%-99% and 87%, 95% CI 72%-99%, respectively).
  
  
  CONCLUSIONS
  Intensive immunochemotherapy can be administered safely to patients with HIV infection. Despite a higher incidence of severe mucositis and infections the remission and survival rates are comparable to those observed in HIV-negative patients.
authors.affiliation: Department of Hematology, ICO-Hospital Universitari Germans Trias i Pujol, Badalona Autonomous University, Barcelona, Spain. aoriol@iconcologia.net
authors.forename: Albert
authors.initials: A
authors.lastname: Oriol
authors.forename: Josep-Maria
authors.initials: JM
authors.lastname: Ribera
authors.forename: Juan
authors.initials: J
authors.lastname: Bergua
authors.forename: Eduardo
authors.initials: E
authors.lastname: Giménez Mesa
authors.forename: Carlos
authors.initials: C
authors.lastname: Grande
authors.forename: Jordi
authors.initials: J
authors.lastname: Esteve
authors.forename: Salut
authors.initials: S
authors.lastname: Brunet
authors.forename: Maria-Jose
authors.initials: MJ
authors.lastname: Moreno
authors.forename: Lourdes
authors.initials: L
authors.lastname: Escoda
authors.forename: Jesus-Maria
authors.initials: JM
authors.lastname: Hernandez-Rivas
authors.forename: Dieter
authors.initials: D
authors.lastname: Hoelzer
mesh_terms: D000293:Adolescent; D000328:Adult; D000911:Antibodies, Monoclonal / Q000008:administration & dosage* / Q000009:adverse effects; D058846:Antibodies, Monoclonal, Murine-Derived; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002051:Burkitt Lymphoma / Q000188:drug therapy*; D004334:Drug Administration Schedule; D005240:Feasibility Studies; D005260:Female; D015658:HIV Infections / Q000188:drug therapy*; D006801:Humans; D007167:Immunotherapy; D016483:Lymphoma, AIDS-Related / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D012074:Remission Induction; D000069283:Rituximab; D016019:Survival Analysis
chemical_list: D000911:Antibodies, Monoclonal; D058846:Antibodies, Monoclonal, Murine-Derived; D000069283:Rituximab